SCHEMBL4348980

SCHEMBL4348980

CCSc1ncc(C(=O)c2cccc(F)c2)c(N)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 1/20 0.48
CCND1 P24385 1/20 0.48
SMN1; SMN2 Q16637 8/20 0.47
NPC1 O15118 6/20 0.47
RAB9A P51151 6/20 0.47
ALDH1A1 P00352 8/20 0.46
LMNA P02545 4/20 0.46
HPGD P15428 2/20 0.46
TSHR P16473 3/20 0.44
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
MAPT P10636 4/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
CDK5 Q00535 1/20 0.42
CDK5R1 Q15078 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4353088 0.85 MAPT (0.47) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL4350416 0.84 SMN1; SMN2 (0.46) CDK4CCND1SMN1; SMN2NPC1RAB9A
SCHEMBL4357734 0.81 SMN1; SMN2 (0.44) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL13621485 0.81 SMN1; SMN2 (0.42) CDK4CCND1SMN1; SMN2NPC1RAB9A
SCHEMBL4351863 0.80 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL4352696 0.80 SMN1; SMN2 (0.49) CDK4CCND1SMN1; SMN2NPC1RAB9A
SCHEMBL4351848 0.79 ALDH1A1 (0.57) SMN1; SMN2NPC1RAB9AALDH1A1LMNA
SCHEMBL4350689 0.79 CDK4 (0.48) CDK4CCND1SMN1; SMN2CDK5CDK5R1
SCHEMBL4352506 0.79 CDK1 (0.51) CDK4CCND1SMN1; SMN2NPC1RAB9A
SCHEMBL13621484 0.79 SMN1; SMN2 (0.44) CDK4CCND1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK4 1/4885CCND1 32/4885SMN1; SMN2 2994/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK4 1/4885CCND1 31/4885SMN1; SMN2 2768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.